The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Hyperfractionated Radiation Therapy With or Without Concurrent Low-Dose Daily Cisplatin in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Prospective Randomized Trial
Abstract
PURPOSE: To investigate whether the addition of cisplatin (CDDP) to hyperfractionation (Hfx) radiation therapy (RT) offers an advantage over the same Hfx RT given alone in locally advanced (stages III and IV) squamous cell carcinoma of the head and neck. PATIENTS AND METHODS: One hundred thirty patients were randomized to receive either Hfx RT alone to a tumor dose of 77 Gy in 70 fractions in 35 treatment days over 7 weeks (group I, n = 65) or the same Hfx RT and concurrent low-dose (6 mg/m 2) daily CDDP (group II, n = 65). RESULTS: Hfx RT/chemotherapy offered significantly higher survival rates than Hfx RT alone (68% v 49% at 2 years and 46% v 25% at 5 years; P = .0075). It also offered higher progression-free survival (46% v 25% at 5 years; P = .0068), higher locoregional progression-free survival (LRPFS) (50% v 36% at 5 years; P = .041), and higher distant metastasis-free survival (DMFS) (86% v 57% at 5 years; P = .0013). However, there was no difference between the two treatment groups in the incidence of either acute or late high-grade RT-induced toxicity. Hematologic high-grade toxicity was more frequent in group II patients. CONCLUSION: As compared with Hfx RT alone, Hfx RT and concurrent low-dose daily CDDP offered a survival advantage, as well as improved LRPFS and DMFS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reporting results of cancer treatment
Miller, A. B., Hoogstraten, B., Staquet, M., & Winkler, A. (1981) · Cancer · doi:10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6 · Cited by 7,793
Cox, J. D., Stetz, J., & Pajak, T. F. (1995) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(95)00060-c · Cited by 4,792
Al-Sarraf, M., LeBlanc, M., Giri, P. G., Fu, K. K., Cooper, J., Vuong, T., Forastiere, A. A., Adams, G., Sakr, W. A., Schuller, D. E., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.4.1310 · Cited by 2,222
Vokes, E. E., Weichselbaum, R. R., Lippman, S. M., & Hong, W. K. (1993) · New England Journal of Medicine · doi:10.1056/nejm199301213280306 · Cited by 2,211
Effects of Concomitant Cisplatin and Radiotherapy on Inoperable Non-Small-Cell Lung Cancer
Schaake-Koning, C., van den Bogaert, W., Dalesio, O., Festen, J., Hoogenhout, J., van Houtte, P., Kirkpatrick, A., Koolen, M., Maat, B., Nijs, A., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199202203260805 · Cited by 1,277
Brizel, D. M., Albers, M. E., Fisher, S. R., Scher, R. L., Richtsmeier, W. J., Hars, V., George, S. L., Huang, A. T., & Prosnitz, L. R. (1998) · New England Journal of Medicine · doi:10.1056/nejm199806183382503 · Cited by 1,127
Tables of the number of patients required in clinical trials using the logrank test
Freedman, L. S. (1982) · Statistics in Medicine · doi:10.1002/sim.4780010204 · Cited by 718
Horiot, J. C., Le Fur, R., N'Guyen, T., Chenal, C., Schraub, S., Alfonsi, S., Gardani, G., Van Den Bogaert, W., Danczak, S., Bolla, M., et al. (1992) · Radiotherapy and Oncology · doi:10.1016/0167-8140(92)90242-m · Cited by 676
Wendt, T. G., Grabenbauer, G. G., Rödel, C. M., Thiel, H. J., Aydin, H., Rohloff, R., Wustrow, T. P., Iro, H., Popella, C., & Schalhorn, A. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.4.1318 · Cited by 634
A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer
Dische, S., Saunders, M., Barrett, A., Harvey, A., Gibson, D., & Parmar, M. (1997) · Radiotherapy and Oncology · doi:10.1016/s0167-8140(97)00094-7 · Cited by 471
Cited by
Argiris, A., Karamouzis, M. V., Raben, D., & Ferris, R. L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60728-x · Cited by 2,224
Adelstein, D. J., Li, Y., Adams, G. L., Wagner, H., Kish, J. A., Ensley, J. F., Schuller, D. E., & Forastiere, A. A. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.008 · Cited by 1,748
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Pfister, D. G., Spencer, S., Adelstein, D., Adkins, D., Anzai, Y., Brizel, D. M., Bruce, J. Y., Busse, P. M., Caudell, J. J., Cmelak, A. J., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0031 · Cited by 1,360
The EGFR as a target for anticancer therapy—focus on cetuximab
Baselga, J. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00233-7 · Cited by 563
Pfister, D. G., Laurie, S. A., Weinstein, G. S., Mendenhall, W. M., Adelstein, D. J., Ang, K. K., Clayman, G. L., Fisher, S. G., Forastiere, A. A., Harrison, L. B., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.4559 · Cited by 496
Salivary Gland Hypofunction/Xerostomia Section, O. C. S. G., Jensen, S. B., Pedersen, A. M. L., Vissink, A., Andersen, E., Brown, C. G., Davies, A. N., Dutilh, J., Fulton, J. S., Jankovic, L., et al. (2010) · Supportive Care in Cancer · doi:10.1007/s00520-010-0827-8 · Cited by 467
Pfister, D. G., Ang, K.-K., Brizel, D. M., Burtness, B. A., Cmelak, A. J., Colevas, A. D., Dunphy, F., Eisele, D. W., Gilbert, J., Gillison, M. L., et al. (2011) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2011.0053 · Cited by 413
Lacas, B., Carmel, A., Landais, C., Wong, S. J., Licitra, L., Tobias, J. S., Burtness, B., Ghi, M. G., Cohen, E. E. W., Grau, C., et al. (2021) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2021.01.013 · Cited by 389
Self-citationMao, L., Hong, W. K., & Papadimitrakopoulou, V. A. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00090-x · Cited by 365
Chronopoulos, A., Zarra, T., Ehrenfeld, M., & Otto, S. (2018) · International Dental Journal · doi:10.1111/idj.12318 · Cited by 317
Pfister, D. G., Su, Y. B., Kraus, D. H., Wolden, S. L., Lis, E., Aliff, T. B., Zahalsky, A. J., Lake, S., Needle, M. N., Shaha, A. R., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.1792 · Cited by 297
Head and Neck Cancers, Version 2.2014
Pfister, D. G., Spencer, S., Brizel, D. M., Burtness, B., Busse, P. M., Caudell, J. J., Cmelak, A. J., Colevas, A. D., Dunphy, F., Eisele, D. W., et al. (2014) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2014.0142 · Cited by 283
Risk factors for osteoradionecrosis after head and neck radiation: a systematic review
Nabil, S., & Samman, N. (2012) · Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology · doi:10.1016/j.tripleo.2011.07.042 · Cited by 277
Huguenin, P., Beer, K. T., Allal, A., Rufibach, K., Friedli, C., Davis, J. B., Pestalozzi, B., Schmid, S., Thöni, A., Ozsahin, M., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.12.193 · Cited by 262
Harrington, K. J., Hingorani, M., Tanay, M. A., Hickey, J., Bhide, S. A., Clarke, P. M., Renouf, L. C., Thway, K., Sibtain, A., McNeish, I. A., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0196 · Cited by 259
Estimation of an optimal external beam radiotherapy utilization rate for head and neck carcinoma
Delaney, G., Jacob, S., & Barton, M. (2005) · Cancer · doi:10.1002/cncr.21084 · Cited by 45
Metadata
- Authors
- Jeremic, B., Shibamoto, Y., Milicic, B., Nikolic, N., Dagovic, A., Aleksandrovic, J., Vaskovic, Z., & Tadic, L.
- Venue
- Journal of Clinical Oncology
- Published
- 2000-04-07
- Volume
- 18
- Issue
- 7
- Pages
- 1458-1464
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1784479792
- Cited by
- 473
- References
- 17
- FWCI
- 24.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.